Drugs / [68Ga]Ga-OncoFAP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05784597 | Apr 2023 → Oct 2024 | breast cancer, colorectal cancer, esophageal cancer, pancreatic adenocarcinoma | Philogen S.p.A. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-01-07 | Philogen S.p.A. | Results Philogen announces publication of PET clinical data with proprietary ultra-high affinity FAP-targeting small molecule ligand (OncoFAP) philogen.com ↗
The data confirmed the rapid and selective accumulation of 68Ga-OncoFAP in solid tumor lesions in disease models and in patient cases. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-01-07 | Philogen S.p.A. | Philogen announces publication of PET clinical data with proprietary ultra-high affinity FAP-targeting small molecule ligand (OncoFAP) philogen.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [68Ga]Ga-OncoFAP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05784597 ↗ |
| Modality | Diagnostic / imaging agent | “for detection/imaging of solid tumors” NCT05784597 ↗ |
| Route | Intravenous | “single intravenous bolus administration” NCT05784597 ↗ |